peptide therapeutics intelligence

Peptide CRO Landscape & Market Intelligence

Independent analysis of the peptide therapeutics industry. Market data, FDA-approved drugs database, development timelines, and CRO selection criteria. A Patient Analog research initiative.

Market Data Drug Database Peptide Calculator
// market_intelligence
Peptide Therapeutics Market Overview

The peptide drug market is one of the fastest-growing segments in pharmaceutical development, driven by GLP-1 agonists and advances in delivery technology.

$49.5B
Global market size (2023)
Grand View Research
9.1%
CAGR 2024-2030
Precedence Research
80+
FDA-approved peptide drugs
FDA Orange Book
170+
Peptides in clinical trials
ClinicalTrials.gov
$50B+
GLP-1 market alone (2024)
Company filings
6-10 yrs
Typical development timeline
Industry average
// approved_therapeutics
Notable FDA-Approved Peptide Drugs

A selection of commercially successful peptide therapeutics across major therapeutic areas.

Drug Name Generic Class Indication Approval
Ozempic Semaglutide GLP-1 Type 2 Diabetes 2017
Wegovy Semaglutide GLP-1 Obesity 2021
Mounjaro Tirzepatide GLP-1/GIP Type 2 Diabetes 2022
Lupron Leuprolide Hormone Prostate Cancer 1985
Sandostatin Octreotide Hormone Acromegaly 1988
Copaxone Glatiramer Immunomod Multiple Sclerosis 1996
Fuzeon Enfuvirtide Antiviral HIV 2003
Vancomycin Vancomycin Antibiotic Bacterial infections 1958
Trulicity Dulaglutide GLP-1 Type 2 Diabetes 2014
Victoza Liraglutide GLP-1 Type 2 Diabetes 2010

Source: FDA approval records. This is not a comprehensive list. Consult FDA Orange Book for complete data.

// peptide_calculator
Peptide Properties Calculator

Enter a peptide sequence (one-letter amino acid codes) to calculate molecular weight, isoelectric point, and other properties.

Example: GLP-1 (7-37) sequence shown. Use standard one-letter codes (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y).

Molecular Weight
3,355.7 Da
Sequence Length
31 aa
Estimated pI
6.8
Hydrophobicity (GRAVY)
-0.42
// cro_selection
Peptide CRO Selection Criteria

Key factors to evaluate when selecting a contract research organization for peptide drug development.

Synthesis Capabilities

Manufacturing scale and chemistry expertise

  • Solid-phase (SPPS) vs solution-phase
  • Scale: mg to kg production
  • Modified amino acids capability
  • Cyclization & stapling expertise
  • GMP certification status

Analytical Services

Characterization and quality control

  • LC-MS / MALDI-TOF
  • Peptide mapping & sequencing
  • Purity analysis (HPLC)
  • Stability studies (ICH guidelines)
  • Impurity profiling

Development Support

Regulatory and clinical pathway

  • CMC documentation
  • IND-enabling studies
  • Process development & validation
  • Tech transfer capabilities
  • Regulatory submission support
// development_timeline
Typical Peptide Drug Development Phases

Standard milestones in peptide therapeutic development from discovery to market.

Year 0-1
Discovery & Lead Optimization
Target identification, sequence design, SAR studies, initial synthesis and screening.
Year 1-2
Preclinical Development
In vitro/in vivo efficacy, ADME studies, toxicology, formulation development.
Year 2-3
IND-Enabling & Filing
GLP toxicology, CMC package, IND submission to FDA.
Year 3-4
Phase I Clinical Trials
First-in-human safety, PK/PD studies, dose escalation.
Year 4-6
Phase II Clinical Trials
Proof-of-concept efficacy, dose optimization, safety in target population.
Year 6-9
Phase III & Approval
Pivotal efficacy trials, NDA/BLA submission, FDA review, market launch.